Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Rheumatoid Arthritis (RA)"

Methotrexate with Step-Down Glucocorticoid Remission Induction Works in Early RA

Reuters Staff  |  August 1, 2016

NEW YORK (Reuters Health)—Methotrexate with step-down glucocorticoid remission induction (COBRA Slim) is an effective, safe and feasible initial treatment strategy for patients with early rheumatoid arthritis (RA), researchers from Belgium report. Patients with early RA should be treated rapidly, intensively and to target, according to current guidelines, they note in a paper online July 18…

FDA Panel Backs Amgen Biosimilar of Humira

Toni Clarke  |  July 13, 2016

(Reuters)—Amgen Inc.’s cheaper version of AbbVie’s top-selling arthritis drug adalimumab (Humira) is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday. The panel voted 26–0 that the drug, ABP 501, which was studied in rheumatoid arthritis and plaque psoriasis, was similar in…

FDA Staff Says Amgen Biosimilar ‘Highly Similar’ to AbbVie’s Humira

Reuters Staff  |  July 8, 2016

(Reuters)—Amgen Inc’s biosimilar form of AbbVie Inc.’s adalimumab (Humira) arthritis drug, the world’s top-selling medicine, is similarly potent and safe as the original product, according to a preliminary review by staff members of the U.S. Food and Drug Administration (FDA). The assessment precedes an all-day meeting on Tuesday of an independent panel of medical advisers…

Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs

Michele B. Kaufman, PharmD, BCGP  |  July 6, 2016

In a recent study, 100% of patients with rheumatoid arthritis (RA) on infliximab experienced a cross-reaction when switched to its biosimilar (CT-P13, infliximab-dyyb). Plus in a recent study, a treat-to-target strategy proved effective for treating RA with biological disease-modifying anti-rheumatic drugs…

Periodontal Infection May Determine Best Treatment for Patients with RA

Lara C. Pullen, PhD  |  July 4, 2016

Past research has indicated that a periodontal pathogen that produces the peptidularginine deiminase (PPAD) enzyme may affect levels of anti-cyclic citrullinated peptide antibody. A new study suggests serum anti-PPAD IgG titers might be a useful biomarker for designing a personalized treatment strategy for RA…

Certolizumab Combo Helps Curb RA Damage

David Douglas  |  June 15, 2016

NEW YORK (Reuters Health)—Certolizumab pegol (Cimzia, UCB Pharma) in combination with methotrexate does better than methotrexate alone in certain patients with early rheumatoid arthritis (RA), according to one-year results from a new trial. As Dr. Paul Emery of the University of Leeds, UK, explains in an email to Reuters Health, “This study used a unique…

Remission of Rheumatoid Arthritis Tied to Lower Risk of Metabolic Syndrome

Reuters Staff  |  June 12, 2016

NEW YORK (Reuters Health)—Disease remission in patients with rheumatoid arthritis (RA) is associated with a lower risk of developing metabolic syndrome, according to a new study from Thailand. Researchers also found that a lower educational level was linked to a higher risk of metabolic syndrome, they report in Joint Bone Spine, online May 26. Dr….

Adalimumab Drives Regulatory T Cell Expansion by Binding to Membrane TNF

Will Boggs, MD  |  June 9, 2016

NEW YORK (Reuters Health)—The anti-tumor necrosis factor (TNF) antibody adalimumab drives regulatory T cell (Treg) expansion in rheumatoid arthritis (RA) by binding to membrane TNF, researchers from the UK report. “These results show that adalimumab enhances the anti-inflammatory actions of TNF to increase regulatory T cell activity,” Dr. Michael R. Ehrenstein from University College London,…

Patients with RA Who Respond to Treatment Experience Increased Cholesterol

Lara C. Pullen, PhD  |  June 6, 2016

New research confirms that patients with rheumatoid arthritis who respond to treatment experience an increase in cholesterol levels, including total cholesterol, LDL-C and HDL-C levels. However, the use of triple therapy may be important for understanding this association and mitigating its risk…

Baricitinib Has Promising Clinical Trial Results for Treating RA

Michele B. Kaufman, PharmD, BCGP  |  May 18, 2016

Recent clinical trials have shown that baricitinib is safe and effective for treating patients with rheumatoid arthritis who have proved non-responsive to multiple biologic treatments…

  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 30
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences